Insiders who reported open-market trades in the last 12 months at the companies Shehnaaz Suliman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Serge Saxonov - $6.82M in TXG purchases and sales in the last 12 months
Adam Taich - $4.84M in TXG purchases and sales in the last 12 months
John R. Stuelpnagel - $2.39M in TXG purchases and sales in the last 12 months
Benjamin J. Hindson - $1.46M in TXG purchases and sales in the last 12 months
Sarah A. Teichmann - $579K in TXG purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Shehnaaz Suliman is a corporate insider, tracked as Director of 10x Genomics, Inc. (TXG). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Shehnaaz Suliman submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Shehnaaz Suliman been buying or selling stock?
Recorded transactions: 0 open-market purchases and 10 open-market sales ($936K) across all tracked filings.
Shehnaaz Suliman is Director of 10x Genomics, Inc. (TXG). 5 SEC Form 4 filings on record, most recently on 24 September 2026. Most recent open-market trade: sold $101K of TXG on 24 September 2026. Lifetime open-market sales: $936K.
Recent transactions
12
The latest 12 SEC Form 4 transactions reported by Shehnaaz Suliman.
InsiderAlpha's records for Shehnaaz Suliman go back to 2026: 5 primary Form 4 filings, an average of 5.0 per year. 12 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
